Detalhe da pesquisa
1.
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Ann Oncol
; 33(3): 288-298, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34921960